With 0.62 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.49 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $29.0 whereas the lowest price it dropped to was $25.25. The 52-week range on QNTM shows that it touched its highest point at $38.25 and its lowest point at $2.70 during that stretch. It currently has a 1-year price target of $35.50. Beta for the stock currently stands at 0.57.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QNTM was up-trending over the past week, with a rise of 26.48%, but this was up by 122.01% over a month. Three-month performance surged to 388.83% while six-month performance rose 686.38%. The stock gained 637.23% in the past year, while it has gained 132.27% so far this year. A look at the trailing 12-month EPS for QNTM yields -14.82 with Next year EPS estimates of -1.15. For the next quarter, that number is -0.17. This implies an EPS growth rate of 73.09% for this year and 67.42% for next year.
Float and Shares Shorts:
At present, 2.71 million QNTM shares are outstanding with a float of 2.38 million shares on hand for trading. On 2025-05-30, short shares totaled 99428.0, which was 342.0 higher than short shares on 1745971200. In addition to Mr. Zeeshan Saeed as the firm’s Founder, CEO, President & Executive Co-Chairman, Mr. Anthony John Durkacz serves as its Founder & Executive Co-Chairman.
Institutional Ownership:
Through their ownership of 0.19900998 of QNTM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, QNTM reported revenue of $0.0 and operating income of -$3385623.0. The EBITDA in the recently reported quarter was -$4671935.0 and diluted EPS was -$3.53.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.18159 being high and -$3.18159 being low. For QNTM, this leads to a yearly average estimate of -$3.18159.
